Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2018 / Cilt: 27 - Sayı: 3

Analysis of Clinical and Laboratory Findings of Secondary Amyloidosis

Sekonder Amiloidozda Klinik ve Laboratuvar Bulgularının Analizi

Pages
267–271
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The need for RRT was similar between the group

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Our aim was to investigate the clinical and laboratory findings of patients with AAamyloidosis.
📊
Key Findings & Data:The patients were divided into 2 groups.
💡
Conclusion & Impact:The need for RRT was similar between the group
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Our aim was to investigate the clinical and laboratory findings of patients with AAamyloidosis. MATERIAL and METHODS: Fifty-nine patients with AA-amyloidosis were included in this study. The patients were divided into 2 groups. Group-1 consisted of 23 patients with AA-amyloidosis due to familial mediterranean fever (FMF) and Group-2 consisted of 36 patients with AA-amyloidosis due to etiologies other than FMF. The laboratory and clinical characteristics of all patients were compared between groups. RESULTS: Of the patients, edema was found in 47 (79.6%), hepatomegaly in 8 (13%), splenomegaly in 9 (14.7%), and hypertension in 21 (35.6%). The median age, systolic/ diastolic blood pressure, serum albumin, total cholesterol, creatinine, and proteinuria values of Group-1 and Group-2 were 29 (16- 73) and 50 (16-76) years (p: 0.001)., 135±12.4 / 73.1±9.2 and 133±13.1 / 72.4±8.9 mmHg (p>0.05), 3.33±0.86 and 2.60±0.92 mg/dl (p:0.04), 238.08±115.68 and 227.77±82.52 mg/dl (p>0.05), 2.51±2.74 and 3.81±3.31 mg/dl (p>0.05), 4.35±3.53 and 5.58±5.10 g/day (p>0.05) respectively. Renal replacement therapy (RRT) was performed in 5 patients in Group-1 and 11 patients in Group-2. CONCLUSION: The most common cause of AA-amyloidosis in our study was FMF, followed by bronchiectasis and chronic obstructive pulmonary disease. Patients with amyloidosis due to FMF were younger than the patients with amyloidosis due to other etiologies. The need for RRT was similar between the group

Özet

AMAÇ: Çalışmamızda AA-amiloidozlu hastaların klinik ve laboratuvar bulgularının incelenmesiamaçlanmıştır.GEREÇ ve YÖNTEMLER: Çalışmaya AA-amiloidoz’u olan 59 hasta dahil edildi. Hastalar iki grubaayrıldı. Grup-1 Ailevi Akdeniz Ateşine (FMF) bağlı AA-amiloidozlu 23 hasta ve Grup-2 FMF hariciAA-amiloidozlu 36 hastadan oluşmaktaydı. Tüm hastaların laboratuvar ve klinik bulguları gruplar arasıkarşılaştırıldı.BULGULAR: Ödem 47 (%79.6), hepatomegali 8 (%13), splenomegali 9 (%14.7), hipertansiyon 21(%35.6) hastada saptandı. Ortanca yaş, sistolik/diastolik kan basıncı, serum albumin, total kolesterol,kreatinin, proteinüri değerleri Grup-1 ve Grup-2 için sırasıyla: 29 (16-73) ve 50 (16-76) (p: 0.001),135±12.4 / 73.1±9.2 ve 133±13.1 / 72.4±8.9mmHg (p > 0.05), 3.33±0.86 ve 2.60±0.92 mg/dl (p:0.04),238.08±115.68 ve 227.77±82.52mg/dl (p>0.05), 2.51±2.74 ve 3.81±3.31mg/dl (p>0.05), 4.35±3.53 ve5.58±5.10 g/gün (p>0.05) idi. Grup-1’de 5 hasta (%21.7), Grup-2’de 11 hasta (%30.6) renal replasmantedavisi (RRT) alıyordu (p: 0,458).SONUÇ: Çalışmamızda en sık neden FMF, ikinci sırada bronşektazi idi. FMF’e bağlı amiloidozuolan hastalar, diğer etiyolojilere bağlı amilodozu olanlara göre daha gençti. RRT ihtiyacı her iki gruptabenzer saptandı.

🔖

Cite This Article

DEDE, F., ODABAŞ, A. R., AYLI, M. D., ATILGAN, K. G. (2022). Analysis of Clinical and Laboratory Findings of Secondary Amyloidosis. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 27 - Sayı: 3, 267–271. https://ajindex.com/articles/636069

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Lachmann HJ, Hawkins PN: Systemic amyloidosis. Curr Opin Pharmacol 2006;6:214-220
  2. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN: Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29
  3. Joss N, McLaughlin K, Simpson K, Boulton-Jones JM: Presentation, Survival and prognostic markers in AA amyloidosis. QJM 2000;93:535-542
  4. Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, Ataman R, Akpolat T, Ok E, Sen S, Dusunsel R, Evrenkaya R, Akoglu E: A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-2005
  5. Gertz MA, Kyle RA: Amyloidosis: Prognosis and treatment. Semin Arthritis Rheum 1994;24:124-138
  6. Queffeulou G, Berenbaum F, Michel C, Mougenot B, Mignon F: AA amyloidosis in systemic lupus erythematosus: An unusual complication. Nephrol Dial Transplant 1998;13:1846-1848
  7. Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R, Kastner DL: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine 1998;77:268-297
  8. Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, Tutar E, Ozen S, Topaloglu R, Yilmaz E, Arici M, Bakkaloglu A, Besbas N, Akpolat T, Dinc A, Erken E: Familial Mediterranean Fever (FMF) in Turkey: Results of a nationwide multicenter study. Medicine 2005;84:1-11 Goldfinger SE: Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302 Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, Gafni J: A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974;291:932-934
  9. Ensari C, Ensari A, Tumer N, Ertug E: Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol Dial Transplant 2005;20:1721-1725
  10. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371